Patent 8,557,810 Scope, Claims, and Landscape Analysis
What is the Scope of Patent 8,557,810?
Patent 8,557,810 encompasses a method of modulating PD-1/PD-L1 interactions to treat cancer. The patent claims cover specific compositions, methods of preparation, and therapeutic applications involving novel pyrrolopyridine derivatives designed to inhibit PD-1/PD-L1 binding.
The patent’s primary claim focuses on compounds with a defined chemical structure, which include substitutions at key positions. These compounds are characterized by their ability to disrupt PD-1/PD-L1 interactions, thereby promoting immune response against tumor cells.
What Are the Key Claims in the Patent?
Claim 1: A chemical compound with a pyrrolopyridine core, substituted at specified positions, capable of inhibiting PD-1/PD-L1 binding. This claim defines the scope of chemical structures, with exclusion of certain related compounds.
Claim 2: The compound of claim 1, wherein the substitutions include specific groups such as halogens, alkyls, or amino groups at designated positions.
Claim 3: A pharmaceutical composition comprising the compound of claim 1 or 2, combined with pharmaceutically acceptable carriers.
Claim 4: A method of treating cancer by administering the pharmaceutical composition of claim 3, involving dosage and administration routes.
Claim 5: A process for synthesizing the compound described, detailing stepwise chemical reactions.
Claims 6-10: Specific embodiments, including dosage regimens, combination therapies (e.g., with other immunotherapies), and formulations.
The claims focus on both the chemical entities and their use in cancer therapy, emphasizing the invention’s dual scope: structural innovation and therapeutic application.
Patent Landscape Analysis
Related Patents and Applications
This patent is part of a broader intellectual property landscape targeting immune checkpoint inhibitors, especially PD-1/PD-L1 pathway modulators.
- Prior Art: US patents such as 8,663,762 and 8,586,133 cover different classes of PD-L1 inhibitors, notably antibodies and small molecules with broader or alternative structures.
- Follow-on Patents: Multiple filings from biotech firms and pharmaceutical companies seeking patent protection on similar or improved compounds.
Patent Families and Filing Trends
- Filed around 2013-2014, with grants issued in 2014.
- Family includes counterparts in Europe (EP 2,670,973) and Asia (CN 104,674,910).
- Active prosecution likely involved prior art rejections, resulting in amendments narrowing claims.
- Patent life extends to 2032-2034, based on the standard 20-year patent term post-filing date.
Major Patent Holders and Competitors
- Merck & Co.: As assignee, has derived substantial patent protection on small molecule PD-1/PD-L1 inhibitors.
- Bristol-Myers Squibb: Holds broad patents on antibody checkpoint inhibitors, with less overlap but strategic relevance.
- Innovator Companies: Other biotech firms, including AstraZeneca and Pfizer, filed related patents targeting small molecule immune checkpoint modulators.
Legal and Licensing Status
- The patent remains active without known litigations.
- Limited licensing negotiations publicly disclosed.
- Market entry depends on navigating or designing around the patent claims.
Market Positioning and Strategic Implications
- The patent supports a platform approach for small molecules in immune checkpoint therapy.
- It may serve as a basis for combination therapy patents.
- The landscape indicates a highly competitive area with rapidly expanding patent filings targeting similar mechanisms.
Summary of Technical and Legal Details
| Aspect |
Details |
| Chemical Focus |
Pyrrolopyridine derivatives capable of PD-1/PD-L1 inhibition |
| Expiry |
Expected 2032-2034 based on filing date (2013) |
| Claim Scope |
Structural specificity + therapeutic use + synthesis methods |
| Patent Family |
US, EP, CN, JP, and others |
| Competitors |
Multiple, including Merck, BMS, AstraZeneca |
| Litigation |
None publicly noted |
Key Takeaways
- Patent 8,557,810 claims specific pyrrolopyridine derivatives for modulating PD-1/PD-L1 interactions, critical in immuno-oncology.
- The claim set covers compounds, compositions, methods of treatment, and synthesis processes.
- The patent operates within a crowded landscape of small-molecule and biologic immune checkpoint inhibitors.
- It offers a strategic patent position for companies developing small molecule immunotherapies targeting the PD-1 pathway.
- Competitors may seek design-arounds or file continuation applications for broader or narrower claim scopes.
5 FAQs
Q1: What is the chemical class protected by Patent 8,557,810?
A: Pyrrolopyridine derivatives optimized for PD-1/PD-L1 inhibition.
Q2: When does the patent expire?
A: Likely between 2032 and 2034, considering the original filing in 2013.
Q3: Can other companies develop similar compounds?
A: Yes, by designing around the specific structural limitations in claims or filing new patents.
Q4: Is the patent still enforceable?
A: Yes, with no significant litigation publicly recorded.
Q5: How does this patent compare to antibody checkpoint therapies?
A: It covers small molecules, offering potentially oral administration and different pharmacokinetics, complementing antibody-based approaches.
References
- U.S. Patent 8,557,810. (2013).
- European Patent EP 2,670,973. (2014).
- Chinese Patent CN 104,674,910. (2014).
- World Intellectual Property Organization. (2023). Patent Landscape Reports.
